| Summary: | ABSTRACT Background Myasthenia gravis (MG) is a rare, autoimmune disorder characterized by fluctuating muscle weakness and potential life‐threatening crises. While continuous specialized care is essential, access barriers often delay timely interventions. To address this, we developed MyaLink, a telemedical platform for MG patients. This study evaluated whether frequently assessed clinical outcomes via MyaLink can capture symptom variability between clinical visits. Methods In this randomized, controlled, 12‐week study, 45 MG patients received either standard care (control, N = 15) or standard care with additional telemedical treatment (intervention, N = 30) including assessment of patient‐reported outcome measures, sensor‐based data, and patient‐physician messaging via a mobile application. Physicians performed telemedical check‐ups (TCUs) via a web‐based platform, adjusting treatment as needed. Results In the intervention group, variability in clinical scores and sensor‐derived data was observed, particularly among those who experienced MG‐related hospitalizations or exacerbations (H&E subgroup). This subgroup showed larger MG‐ADL score fluctuations (mean range: 5.8 vs. 2.6 points), sent more messages, had more steroid dose adjustments (40% vs. 0%), and more frequent TCU interventions (93.3% vs. 60%) than the Non‐H&E subgroup. Interpretation Telemedical platforms in MG might detect early signs of worsening. High‐risk patients (H&E subgroup) require increased medical support, which can be effectively addressed through MyaLink. Trial Registration The study was registered under the German clinical trial registry (DRKS00029907)
|
|---|
